Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B7VK
|
|||
| Former ID |
DIB002318
|
|||
| Drug Name |
Tifacogin
|
|||
| Synonyms |
LACI; SC-59735; TFP-561; LACI, Pharmacia/Chiron; LACI, Searle/Chiron; Lipoprotein associated coagulation inhibitor, Pharmacia/Chiron;Lipoprotein associated coagulation inhibitor, Searle/Chiron; RTFPI, Pharmacia/Chiron; RTFPI, Searle/Chiron; Tissue factor pathway inhibitor, Pharmacia/Chiron; Tissue factor pathway inhibitor, Searle/Chiron
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sepsis [ICD-11: 1G40-1G41; ICD-9: 995.91] | Phase 3 | [1] | |
| Company |
GD Searle & Co; Chiron
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H13NS
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CNCC2=CC=CS2
|
|||
| InChI |
1S/C12H13NS/c1-2-5-11(6-3-1)9-13-10-12-7-4-8-14-12/h1-8,13H,9-10H2
|
|||
| InChIKey |
GEWKIDGKZRKUFB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 73325-61-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue factor pathway inhibitor (TFPI) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Syndecan-4-mediated signaling events | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Integrated Breast Cancer Pathway | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.